Aurinia Pharmaceuticals Inc. (AUPH)
$
11.99
-0.09 (-0.75%)
Key metrics
Financial statements
Free cash flow per share
0.6650
Market cap
1.6 Billion
Price to sales ratio
6.0676
Debt to equity
0.2440
Current ratio
5.2254
Income quality
1.5282
Average inventory
46.3 Million
ROE
0.1672
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company based in Victoria, Canada, is dedicated to developing and commercializing therapies aimed at addressing various diseases with unmet medical needs, both in the United States and internationally. The company’s offering, LUPKYNIS, is specifically designed for the treatment of adult patients suffering from active lupus nephritis. In terms of financial performance, the income before tax ratio is 0.03 reflecting the pre-tax margin. Furthermore, the company incurred an income tax expense of $1,696,000.00 indicating its tax obligations. The total costs and expenses for the company are $239,820,000.00 reflecting its overall spending in pursuit of its therapeutic goals. The operating income ratio is -0.02 which indicates the company's operational profitability margin, highlighting its efficiency in generating income from its core operations. Additionally, the gross profit stands at $206,885,000.00 showcasing the company’s profitability derived from its primary activities. Aurinia's collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd emphasizes its strategic partnerships in advancing healthcare solutions. In the financial market, Aurinia Pharmaceuticals is viewed as an appealing option for investors. The stock is affordable at $9.04 making it suitable for budget-conscious investors. It boasts a high average trading volume of 2,008,255.00 indicating strong liquidity in the market, which enhances its attractiveness to potential buyers. With a market capitalization of $1,578,243,700.00 the company is classified as a small-cap player, positioning it uniquely within the market. As a key player in the Biotechnology industry, Aurinia contributes significantly to the overall market landscape, driving innovation and growth. The company operates within the Healthcare sector, which is instrumental in fostering advancements that can change the healthcare paradigm. This combination of strong liquidity, strategic positioning, and a clear focus on unmet medical needs underscores Aurinia Pharmaceuticals' role in shaping the future of biopharmaceuticals.
Is Aurinia Pharmaceuticals Inc. (AUPH) a good investment?
Investing in Aurinia Pharmaceuticals Inc. (AUPH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Aurinia Pharmaceuticals Inc. (AUPH)'s stock forecast?
Analysts predict Aurinia Pharmaceuticals Inc. stock to fluctuate between $6.42 (low) and $12.53 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aurinia Pharmaceuticals Inc.'s market capitalization?
As of 2025-08-29, Aurinia Pharmaceuticals Inc.'s market cap is $1,578,243,700, based on 131,630,000 outstanding shares.
How does Aurinia Pharmaceuticals Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Aurinia Pharmaceuticals Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aurinia Pharmaceuticals Inc. (AUPH) stock?
To buy Aurinia Pharmaceuticals Inc. (AUPH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AUPH. Place an order (Market, Limit, etc.).
What is the best time to invest in Aurinia Pharmaceuticals Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Aurinia Pharmaceuticals Inc. stock ever split?
Aurinia Pharmaceuticals Inc.'s last stock split was 1:50 on 2013-11-08.
How did Aurinia Pharmaceuticals Inc. perform in the last earnings report?
Revenue: $235,133,000 | EPS: $0.04 | Growth: -107.41%.
Where can I find Aurinia Pharmaceuticals Inc.'s investor relations reports?
Visit https://www.auriniapharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aurinia Pharmaceuticals Inc.?
You can explore historical data from here
What is the all-time high and low for Aurinia Pharmaceuticals Inc. stock?
All-time high: $33.97 (2021-11-03) | All-time low: $4.07 (2022-12-28).
What are the key trends affecting Aurinia Pharmaceuticals Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
fool.com
Aurinia Pharmaceuticals (AUPH 2.15%), a biopharmaceutical company focused on therapies for autoimmune diseases, released its second-quarter 2025 earnings on July 31, 2025. The headline news: revenue (GAAP) came in at $70.0 million, which exceeded analyst expectations of $63.8 million by 9.7% (GAAP).
businesswire.com
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025.
seekingalpha.com
I revisit biopharma name Aurinia Pharmaceuticals Inc. for the first time in 2025 after the company reported solid Q1 results in May. The quarter saw Lupkynis net product revenues up 25% year-over-year to $60 million and management reaffirm FY2025 guidance. The company has a strong balance sheet, a free cash flow turnaround, and projected profit growth to $0.59/share in FY2025 to support a positive investment outlook.
proactiveinvestors.com
Shares of Aurinia Pharmaceuticals (TSX:AUP)(NASDAQ:AUPH) jumped 6.8% to $8.57 on Thursday afternoon as investors looked ahead to the company's first clinical data update for its experimental autoimmune drug AUR200, which Jefferies said could carry significant strategic value. Jefferies upgraded its outlook on the BAFF/APRIL dual inhibitor, noting the upcoming results from a single ascending dose (SAD) study in healthy volunteers could provide important insight into safety, pharmacokinetics and the company's development roadmap.
zacks.com
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
businesswire.com
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis.
seekingalpha.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Andrea Christopher - Corporate Communications and IR Peter Greenleaf - President and CEO Joe Miller - CFO Greg Keenan - CMO Conference Call Participants Stacy Ku - TD Cowen Maury Raycroft - Jefferies Joseph Schwartz - Leerink Partners Olivia Brayer - Cantor Fitzgerald Sahil Dhingra - RBC Capital Markets David Martin - Bloom Burton Operator Greetings, and welcome to the Aurinia Pharmaceuticals Inc. Q1 2025 Earnings Call. At this time, all participants are in a listen-only mode.
businesswire.com
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025.
businesswire.com
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025.
See all news
